Komori
SanBio (4592) · FactRestated

Focus on the regenerative cell business using allogeneic stem cells

First written in FY2017-Q1. 24 of 27 entries say "Restated". Latest entry: FY2027-H1.

27entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2024-Q32016: 320162017: 420172018: 220182019: 320192020: 320202021: 120212022: 320222023: 420232024: 120242025: 220252026: 12026
Same theme, other companies
Single-segment integration of the regenerative medicine-related businessA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

SanBio moved to the "Worse" side of this theme in 2024.

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1RestatedAnnual report

    「As the Group operates a single segment, the cell therapy drug business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the cell therapy drug business using allogeneic stem cells was reaffirmed.
  2. FY2026-H1RestatedAnnual report

    「As the Group operates a single segment, the cell therapy drug business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the cell therapy drug business using allogeneic stem cells was reaffirmed.
  3. FY2025ReframedAnnual report

    「As the Group operates a single segment, the cell therapy drug business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure was maintained, but the segment name and description were changed from “Cell Therapy Drug Business” to “Cell Therapy Drug Business Using Allogeneic Stem Cells.”
  4. FY2025-H1ReframedAnnual report

    「From the current interim consolidated accounting period, the segment name previously used, “Regenerative Cell Business,” has been changed to “Cell Therapy Drug Business.”」

    The single-segment structure using allogeneic stem cells was maintained, but the segment name was changed from “Regenerative Cell Business” to “Cell Therapy Drug Business.”
  5. FY2024-Q3RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  6. FY2024-Q2RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  7. FY2024-Q1RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  8. FY2023RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  9. FY2023-Q3RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  10. FY2023-Q2RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  11. FY2023-Q1RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  12. FY2022-Q2RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  13. FY2021-Q3RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  14. FY2021-Q1RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  15. FY2020RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  16. FY2020-Q3RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  17. FY2020-Q1RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  18. FY2019RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    The single-segment structure comprising the regenerative cell business using allogeneic stem cells was reaffirmed.
  19. FY2019-Q3RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  20. FY2019-Q2RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  21. FY2018-Q3RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  22. FY2018-Q2RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  23. FY2018-Q1RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  24. FY2017RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  25. FY2017-Q3RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  26. FY2017-Q2RestatedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was reaffirmed that the Group consists of a single segment, the regenerative cell business using allogeneic stem cells.
  27. FY2017-Q1First statedAnnual report

    「As the Group operates a single segment, the regenerative cell business using allogeneic stem cells, segment-by-segment results are omitted.」

    It was disclosed that the Group's business consists of a single segment, the regenerative cell business using allogeneic stem cells.
Moved together

"Management Objectives Focused on Development Program Progress and Pipeline Expansion" moved the same way as this thread, in the same document, in 2 of its 27 moves.

222★123
  1. ★This thread
  2. 1Management Objectives Focused on Development Program Progress and Pipeline Expansion2×
  3. 2Liquidity Risk Associated with Upfront R&D Investment2×
  4. 3Dilution Through Issuance of New Shares and Exercise of Stock Acquisition Rights2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for SanBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Focus on the regenerative cell business using allogeneic stem cells | SanBio Company Limited (4592) | Komori